Regeneron Pharmaceuticals, Inc. (REGN)
955.36
+4.17
(+0.44%)
USD |
NASDAQ |
Nov 13, 16:00
955.36
0.00 (0.00%)
After-Hours: 19:59
Regeneron Pharmaceuticals Enterprise Value : 91.75B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 91.75B |
| November 11, 2026 | 92.60B |
| November 10, 2026 | 88.11B |
| November 09, 2026 | 88.52B |
| November 06, 2026 | 86.90B |
| November 05, 2026 | 86.75B |
| November 04, 2026 | 89.62B |
| November 03, 2026 | 94.04B |
| November 02, 2026 | 92.79B |
| October 30, 2026 | 89.34B |
| October 29, 2026 | 78.05B |
| October 28, 2026 | 77.49B |
| October 27, 2026 | 77.78B |
| October 26, 2026 | 76.91B |
| October 23, 2026 | 76.63B |
| October 22, 2026 | 78.09B |
| October 21, 2026 | 76.70B |
| October 20, 2026 | 76.89B |
| October 19, 2026 | 74.26B |
| October 16, 2026 | 75.16B |
| October 15, 2026 | 75.73B |
| October 14, 2026 | 73.88B |
| October 13, 2026 | 71.27B |
| October 12, 2026 | 72.27B |
| October 09, 2026 | 70.59B |
| Date | Value |
|---|---|
| October 08, 2026 | 69.86B |
| October 07, 2026 | 70.13B |
| October 06, 2026 | 69.78B |
| October 05, 2026 | 68.51B |
| October 02, 2026 | 69.41B |
| October 01, 2026 | 69.37B |
| September 30, 2026 | 71.80B |
| September 29, 2026 | 72.30B |
| September 28, 2026 | 72.48B |
| September 25, 2026 | 76.19B |
| September 24, 2026 | 77.01B |
| September 23, 2026 | 77.61B |
| September 22, 2026 | 77.83B |
| September 21, 2026 | 77.23B |
| September 18, 2026 | 75.86B |
| September 17, 2026 | 76.33B |
| September 16, 2026 | 74.80B |
| September 15, 2026 | 74.74B |
| September 14, 2026 | 76.77B |
| September 11, 2026 | 75.51B |
| September 10, 2026 | 76.72B |
| September 09, 2026 | 78.21B |
| September 08, 2026 | 78.49B |
| September 04, 2026 | 80.29B |
| September 03, 2026 | 81.92B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 226.62B |
| AbbVie, Inc. | 590.62B |
| Vertex Pharmaceuticals, Inc. | 137.73B |
| Amgen, Inc. | 293.45B |
| Biogen, Inc. | 43.52B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.949B |
| Revenue (Quarterly) | 5.116B |
| Total Expenses (Quarterly) | 3.167B |
| EPS Diluted (Quarterly) | 18.45 |
| Gross Profit Margin (Quarterly) | 86.42% |
| Profit Margin (Quarterly) | 38.09% |
| Earnings Yield | 4.74% |
| Operating Earnings Yield | 5.04% |
| Normalized Earnings Yield | 5.111 |